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Background: The goal of this study was to evaluate the prevalence of suspected hypertrophic cardiomyopathy
(HCM) in a population of teenagers undergoing screening echocardiography for the detection of HCM.
Method: The Anthony Bates Foundation performs screening echocardiography for the prevention of sudden
death. A total of 2,066 students were studied between the ages of 13 to 19 years. Suspected HCM was defined as
any wall thickness ≥ 15 mm. LVH was defined as wall thickness ≥ 13 mm
Results: Prevalence of suspected HCM was 0.7% (14/2066). After adjusting for hypertension (HTN), the total
prevalence was 0.5% (8/1457). In a subgroup analysis, 551 teenagers with documented race and LV wall thickness
were identified between the ages of 13 - 19 years. African American teenagers [6% (3/50)] had higher prevalence
of suspected HCM [0.8% (4/501), OR 7.93, CI 1.72-36.49, p = 0.002]. After multivariate adjustment for age, gender,
BMI and HTN (systolic BP >140 and diastolic BP of > 90), African American race remained independently associated
with suspected HCM (OR 4.89, CI 1.24-39.62, p = 0.02).
Conclusion: The prevalence of suspected HCM in young teenagers is approximately 0.2%. This prevalence appears
to be higher in African Americans. However, due to small number of African Americans in our population, our
result needs to be confirmed in larger trials.
Introduction
Hypertrophic cardiomyopathy (HCM) is a common
cause of sudden death in young people [1,2]. HCM is a
relatively common genetic disorder with an estimated
prevalence of 1 in 500 young adults [3]. Several periodic
screening programs for early identification of HCM
have been in practice across the country including Ant-
ony Bates Foundation and A Heart for Sport. HCM has
been extensively studied for the last 40 years; however,
there have been no prior studies in literature measuring
prevalence of HCM in healthy teenagers prospectively in
a large population.
We conducted this study to evaluate the prevalence of
suspected HCM in a population of healthy teenagers
who underwent voluntary health screening examination
using echocardiography. We also evaluated for any race,
gender and age range differences (13 -15 years vs. 16
-19 years) in the prevalence of HCM.
Methods
The Anthony Bates Foundation has been conducting
periodic health screening evaluations for high school
students since 2001 for the detection of hypertrophic
cardiomyopathy in early age. The evaluation includes
history and physical examination, electrocardiogram and
hand held echocardiogram. Board certified cardiologists
reviewed these echocardiograms on site. Inform consent
was obtained before the procedure. Participants were
recruited using advertisement by the Antony Bates
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years. Informed consent of teenagers younger than 18
was obtained from their parents.
The Anthony Bates Foundation targets young people
in puberty. The program is voluntary. Participants are
not required to be engaged in any athletic activities. The
populations studied were volunteers screened for pre-
vention of sudden death in young students. Although
the screening was aimed for young subjects, no volun-
teer would be excluded for any reasons irrespective of
age or comorbidities. This program was designated to
report any suspected abnormal echocardiographic find-
ings to the participant with recommendation to be fol-
lowed by the participant’s physician. Further follow up
and work up was not included in the data base.
We used different models of hand held/mobile echo
devices from Cypress (Siemen), Optigo (Philips), Vividi
(GE), Sequoia (Simens) and SonoSite (GE). Different
echo devices used for our study had different capabil-
ities. However, for function and measurements used in
our study, all echo devices used were appropriate and
accurate. The hand held devices were all donated by the
Regional Echocardiography Manufacturers Sales Force,
local echocardiography companies, and participating
hospitals during the screening.
Left ventricular septum and posterior wall were mea-
sured in the standard parasternal long axis view below
the tip of the mitral valve. Furthermore, the entire left
ventricle (LV) was routinely visualized to assess for loca-
lized hypertrophy. The correct position was confirmed
by on site cardiologist. Wall thickness in end diastole
was measured in the standard parasternal long axis view
below the tip of the mitral valve and was confirmed by
reading cardiologist at site. Other views were also
reviewed to evaluate for occurrence of localized abnor-
mal wall thickness. The obtained information is being
continuously incorporated into a database.
Suspected HCM was defined as any wall thickness ≥15
mm based on the current guidelines[4]. Hypertension
was defined as a systolic blood pressure > 140 mmHg or
diastolic blood pressure > 90 mm. The diagnosis of
hypertension was based on one blood pressure measure-
ment during the screening. We used SPSS 15.0 to con-
duct statistical analysis. Height and weight were
available which were used for BMI calculation. Obesity
was defined in subjects with a BMI of over 30. We used
univariate and multiple regression analysis adjusting for
comorbidities. Furthermore, in order to evaluate for
possible late expression of HCM genes in life, we com-
pared the prevalence of HCM in two different age
groups (13-16 and 16-19). Data analysis was performed
in blinded fashion. A p value of less than 0.05 was
deemed to be statistically significant. Multivariable ana-
lysis was performed in only a subset of patients due to
the lack of data and this may lower the power of the
model. Study period includes data from 2001-2009.
Results
A total of 2,066 teenagers were identified between the
ages of 13 - 19 years with documented left ventricular
wall thickness. The total prevalence of suspected HCM,
d e f i n e db yac u to f fv a l u eo f1 5m mo rm o r e ,w a s0 . 7 %
(14/2066). After excluding teenagers with hypertension
documented during screening, the prevalence of sus-
pected HCM decreased to 0.5% (8/1457). There was no
difference between the gender or age ranges using the
cut off of ≥ 15 mm. We found 0.4% (3/688) of females
vs. 1.1% (15/1377) of males had suspected HCM,
p = 0.3 and 0.2% in teenagers between the age of 13-15
years vs. 0.3% between the age of 16-19 years, had sus-
pected HCM, p = 0.7. Using a cut off value of 13 mm
or more for the presence of left ventricular hypertrophy
(LVH), [4] LVH occurred in 2.8% (57/2066) of the study
population with a higher prevalence in male (3.6% in
male vs. 1% in females, p = 0.001). Furthermore, African
Americans had a higher mean posterior or septal wall
thickness in comparison to other races (Table 1)
Sub group analysis showing race based prevalence
A total of 551 teenagers with documented race demogra-
phy and LV wall thickness were identified between the
ages of 13 - 19 years. The estimated prevalence of HCM
was 1.3% (7/551) in this population. African American
teenagers [6% (3/50)] had higher prevalence compared
to all other races [0.8% (4/501), OR 7.93, CI 1.72-36.49,
p = 0.002] (Figure 1). The mean age of African American
group was 17.0 ± 1.6 year vs. 16.3 ± 1.7 in all other races,
p = 0.027. None of the African American subjects with
suspected HCM had large left ventricular size over 5.7
cm. Overweight was more prevalent in African American
race [(16.3% (8/49) vs. 9.8% (44/449) in all other races,
p = 0.151)]. Only 12% (6/50) of the African American
were female vs. 39% (196/503) of all other races (p <
0.001). After multivariate adjustment for age, gender,
BMI and HTN (systolic BP >140 and diastolic BP of >
90), African American race remained independently
Table 1 Mean differences in between African American
and other races.
AA Others p
BMI 25.7 ± 4.8 23.4 ± 4.6 0.001
Age 17.0 ±1.6 16.3 ± 1.7 0.004
PWT D 0.96 ± 0.20 086 ± 0.28 0.015
SWTD 0.99 ± 0.21 0.85 ± 0.16 < 0.001
LVDED 4.8 ± 0.55 4.6 ± 0.58 0.026
AA = African Americans, BMI = Body Mass Index, PWTD = Posterior wall
Thickness in Diastole, SWTD = Septal Wall Thickness in Diastole, LVEDD = Left
Ventricular Dimension in End Diastole
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p = 0.02). There was no significant difference in the pre-
valence of LVH or suspected HCM between other races.
Discussion
Our study showed three important findings. First of all,
the estimated prevalence of suspected HCM across the
study population, after adjusting for hypertension, was
0.5%. Second, there was no significant gender difference
and age range difference in the prevalence of HCM.
African American race appears to have higher preva-
lence of HCM compared to all the other races indepen-
dent of age, gender, BMI and HTN. However, we had
small number of African Americans in our population,
limiting our result that needs to be confirmed in larger
studies.
The estimated prevalence of suspected HCM in our
study is 1 in every 200 study subjects. Hada et al studied
12 000 adult Japanese workers initially with EKGs and
subsequently with echocardiograms and reported preva-
lence of HCM was 0.2%[5]. A recent community-based
study of patients referred for echocardiography because
of a suspicion of cardiovascular disease demonstrated a
0.5% prevalence for HCM [5]. In a more recent echocar-
diogram based study of 4,111 young adults, Maron et al
demonstrated a HCM prevalence of 0.2% (3). ECG
based identification of HCM underestimates the preva-
lence of HCM compared to echo based studies. There is
variability in the echo-based definition of HCM based
on different HCM forms. In the consensus document
HCM is defined if the septum thickness was >15 in the
isolated form and >13 mm in the familial form [4].
In our study the prevalence increased to 2.8% from
0.5% when the echo definition of HCM was changed to
≥ 13 mm. Relaxing the cutoff for the wall thickness
grossly overestimates the prevalence of HCM. Mildly
increased LV wall thickness of 13 to 14 mm can also be
seen in certain extreme expressions of the physiologi-
cally-based athletes heart [6-8] Our study has slightly
higher prevalence than the general population probably
secondary to above mentioned reasons.
Our study showed no significant gender differences in
the prevalence of HCM. Similar findings were reported in
prior studies [10,11]. Even though our study showed small
numerical differences with increased males compared to
females having HCM, the overall prevalence of condition
is so low that it limits statistical power to identify any
significant differences. There were also no significant dif-
ferences in prevalence between the two age groups 13-15
vs. 16-19 years.
Over the years, HCM was considered an uncommon
condition among the African American population. This
was based on prior literature, which included relatively
small number of African American patients[3,5,9-12].
Maron et al (2003), in a multi center analysis of clini-
cally diagnosed HCM patients noted only 8% of the
Figure 1 Prevalence of Suspected Hypertrophic Cardiomyopathy (in p e r c e n t )b a s e do nt h eA f r i c a nA m e r i c a nr a c ei nt h es c r e e n e d
teenagers.
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Americans constitute only 9% of the population. More-
over, blacks had significantly higher prevalence of HCM
compared to other races (6% vs. 0.8%). However, in the
light of several premature cardiovascular deaths among
African American athletes, Maron et al, in an autopsy
analysis of young athletes surprisingly noted HCM was
7 times more commonly identified in African Americans
for the first time at autopsy compared to when clinically
identified in African American population[12]. Although
African Americans constitute only 9% of our study
population, they have a significant association with
HCM using uni-variate and multi-variate analysis.
Even though African Americans constitute 16% of the
population across United States, small numbers of Afri-
can Americans participate in the screening events.
Inadequate access to health care secondary to socio-
economic reasons may contribute to decreased numbers
of African Americans undergoing screening for diagno-
sis of HCM[13-15].
Our study focused on the age, gender and race based
prevalence of suspected HCM in healthy teenagers
between ages of 13-19 years. We conclude that preva-
lence of suspected HCM in the teenage population is
similar to that reported in general population. African
Americans have significantly higher prevalence of HCM
compared to other races. A recent study reported that
African American athletes exhibited greater LV wall
thickness and cavity size compared to sedentary African
Americans and Caucasians. In addition, the authors
reported 3% of African Americanathletes in this study
exhibited an LV wall thickness >= 15 mm, despite nor-
mal LV diastolic function and an enlarged LV cavity
consistent with over diagnosis of HCM in this popula-
tion[16]. These results could explain our finding of a
higher prevalence of suspected HCM in our African
American population. Therefore, it is important to
recognize that the diagnosis of HCM in African Ameri-
cans should be made with extreme caution based on LV
wall thickness alone. It is possible that suspected HCM
in our African American population does not represent
true HCM. Data about LV volume in our subjects,
which would have been useful in assessing the left ven-
tricular dilation that could occur in the athletic heart,
was not available for this study. However, we LV dimen-
sion was available as measured in standard parasternal
long axis view. All African American subjects in our
population with suspected HCM had normal left ventri-
cular size suggesting that abnormal LV wall thickness
was not related to athlete heart condition that should
manifest as left ventricular dilatation in addition to left
ventricular hypertrophy[17]. Furthermore, LV wall thick-
ness greater or equal to 13 mm is very uncommon in
highly trained athletes without cavity dilatation [8].
We suggest increased screening of African American
teenagers for making early diagnosis of HCM by over-
c o m i n gt h ep o s s i b l ec h a l l e n g e sl i k el a c ko fa c c e s st o
health care, which might help decrease morbidity and
mortality associated with HCM in African American
population. We also hope that our study will instigate
further evaluation of the genetic make-up of HCM in
African American population in order to better under-
stand the disease and possible interventions to decrease
associated morbidity and mortality.
Italian physicians have been the most experience
with HCM screening programs. They have been suc-
cessful in detecting early cardiac abnormalities includ-
ing HCM in asymptomatic athletes [18-21]. For more
than 20 years, 33,735 young athletes underwent
screening leading to disqualification of athletes from
training in 3.5% of participants[21]. None of the dis-
qualified athletes died during a mean follow-up period
of 8.2 years suggesting effective prevention. However,
significant cardiac abnormalities in asymptomatic
highly trained athletes have found to be extremely rare
in England[22]. Future studies are needed to evaluate
the cost effectiveness of routine screening for HCM in
asymptomatic athletes.
Limitations
Our study is a retrospective review of a data base. We
used only echocardiographic measurement of wall thick-
ness suspecting HCM. However HCM was not con-
firmed clinically or by further testing. Lack of significant
differences in the prevalence of HCM between males
and females could be due to small numbers of subjects
and lack of sufficient statistical power. Our data base
was acquired over many years and as time passed, new
parameters were added to the questionnaire including
adding more demographics such as race or gender
which are not available in subjects with earlier screening
date. Therefore, the number of subjects is lower in the
multivariate analysis when adjusting for parameters that
are not available in every participant limiting our multi-
variate analysis. The definition of hypertension was used
using only single measurement of blood pressure. This
may have increased the number of hypertensive sub-
group. One of the major problems in the diagnosis of
HCM is the differential diagnosis with LVH. We could
not separate this two entities based on available data.
This is the reason why we only used suspected HCM
and not definite HCM in our manuscript. We have no
outcome data as this study was performed at one time
without follow up data availability. Our study is limited
due to small number of African American participants
but our results is highly significant and is consistent
with previous reported studies that needs to be con-
firmed in larger trials.
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